BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20526888)

  • 1. A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma.
    Hongo A; Kusumoto T; Nakamura K; Seki N; Kodama J; Hiramatsu Y
    Int J Clin Oncol; 2010 Oct; 15(5):476-83. PubMed ID: 20526888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
    Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
    Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
    Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
    J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).
    Yamada K; Tanabe H; Imai M; Jobo T; Kudo K; Fujiwara H; Nagata C; Furuya K; Suzuki M; Ochiai K; Tanaka T; Yasuda M
    J Obstet Gynaecol Res; 2013 Jan; 39(1):311-6. PubMed ID: 22639962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
    Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
    J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Papadimitriou CA; Bafaloukos D; Bozas G; Kalofonos H; Kosmidis P; Aravantinos G; Fountzilas G; Dimopoulos MA;
    Gynecol Oncol; 2008 Jul; 110(1):87-92. PubMed ID: 18455782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
    Michener CM; Peterson G; Kulp B; Webster KD; Markman M
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
    Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
    Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of paclitaxel and carboplatin in patients with endometrial cancer].
    Nakamura T; Onishi Y; Yamamoto F; Kouno S; Maeda Y; Hatae M
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):257-62. PubMed ID: 10700897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
    Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
    Miller DS; Filiaci VL; Mannel RS; Cohn DE; Matsumoto T; Tewari KS; DiSilvestro P; Pearl ML; Argenta PA; Powell MA; Zweizig SL; Warshal DP; Hanjani P; Carney ME; Huang H; Cella D; Zaino R; Fleming GF
    J Clin Oncol; 2020 Nov; 38(33):3841-3850. PubMed ID: 33078978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.
    Sato S; Shimada M; Ohta T; Kojimahara T; Tokunaga H; Takano T; Yamaguchi S; Tanabe H; Nishio S; Kigawa J
    Int J Gynecol Cancer; 2016 Mar; 26(3):561-7. PubMed ID: 26825829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
    Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
    J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer.
    Wen Q; Shao Z; Yang Z
    Int J Gynecol Cancer; 2013 May; 23(4):685-9. PubMed ID: 23615571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
    Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.